ClearPoint Neuro (CLPT) COO receives 36,818 restricted stock units in equity grant

Rhea-AI Filing Summary

ClearPoint Neuro, Inc. reported that Chief Operating Officer Sabra Mazin acquired 36,818 restricted stock units (RSUs) of company stock as a compensation award. Each RSU represents a contingent right to receive one share of CLPT common stock if vesting conditions are met.

The award vests over three years: 20% of the RSUs on February 17, 2027, 40% on February 17, 2028, and the remaining 40% on February 17, 2029. After this grant, Mazin directly holds 36,818 RSUs, aligning part of her compensation with the company’s future performance.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider SABRA MAZIN

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	36,818	$0.00	--

Holdings After Transaction: Restricted Stock Units — 36,818 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SABRA MAZIN

(Last) (First) (Middle)

C/O CLEARPOINT NEURO, INC.

120 S. SIERRA AVE., SUITE 100

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ClearPoint Neuro, Inc. [ CLPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/17/2026		A		36,818		(2)	(2)	Common Stock	36,818	$0	36,818	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of CLPT common stock.

2. The restricted stock units vest as follows: (i) 20% of the total shares on February 17, 2027; (ii) 40% of the total shares on February 17, 2028; and (iii) 40% of the total shares on February 17, 2029.

	/s/ Danilo D'Alessandro, by Power of Attorney for Mazin Sabra	02/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ClearPoint Neuro (CLPT) report for Sabra Mazin?

ClearPoint Neuro reported that Chief Operating Officer Sabra Mazin received a grant of 36,818 restricted stock units. These RSUs are a form of equity compensation that convert into common shares over time if vesting conditions are satisfied.

How many restricted stock units did CLPT’s COO receive in this Form 4?

The Form 4 shows that CLPT’s COO, Sabra Mazin, was granted 36,818 restricted stock units. Each RSU corresponds to one share of ClearPoint Neuro common stock, giving her a future equity stake tied to the company’s performance.

What is the vesting schedule for Sabra Mazin’s CLPT restricted stock units?

The RSUs vest in three tranches: 20% of the total on February 17, 2027, 40% on February 17, 2028, and the final 40% on February 17, 2029. Vesting must occur before shares are actually delivered.

Does the CLPT Form 4 indicate a stock purchase or sale by the COO?

The Form 4 reflects an equity award, not an open-market stock purchase or sale. It records a grant of restricted stock units to the COO as part of compensation, categorized as an acquisition under code “A.”

What does each ClearPoint Neuro restricted stock unit represent for the COO?

Each restricted stock unit represents a contingent right to receive one share of CLPT common stock. The shares are only delivered if the specified vesting dates are reached and any applicable conditions are met.